Clinical trials: Respiratory Inflammation
Sepsis, Respiratory Failure
Safety, Tolerability and Performance of the NucleoCapture Device in the Reduction of Circulating CfDNA/NETs in Subjects with Sepsis
This is a prospective, multinational, multicentre, randomised, parallel-group, open-label study to assess the safety, tolerability and performance of the NucleoCapture extracorporeal apheresis device in the reduction of…
- Trial name
- NUC-CAP (NCT05647096)
- Testing
- NucleoCapture device
- Where
- 9 sites in Germany, Switzerland and 1 more
- Volunteers
- 73 people
- Sponsor
- Santersus AG
COVID
Study of Mavrilimumab (KPL-301) in Participants Hospitalized With Severe Corona Virus Disease 2019 (COVID-19) Pneumonia and Hyper-inflammation
Interventional, randomized, double-blind, placebo-controlled study encompassing 2 development phases (Phase 2 and Phase 3).
- Trial name
- NCT04447469
- Testing
- mavrilimumab
- Where
- 32 sites in United States, Brazil and 3 more
- Volunteers
- 814 people
- Sponsor
- Kiniksa Pharmaceuticals International, plc
Asthma
A Safety and Efficacy Study of Mepolizumab in Subjects With Severe Asthma
Mepolizumab, a humanized monoclonal antibody, has been developed as an add-on treatment for subjects with severe asthma with eosinophilic inflammation.
- Trial name
- NCT03562195
- Testing
- Mepolizumab 100 milligrams, Salbutamol
- Where
- 42 sites in China
- Volunteers
- 300 people
- Sponsor
- GlaxoSmithKline
Asthma
Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma
This study is researching a drug called dupilumab. The study is focused on patients who have uncontrolled asthma. Asthma is a condition where the airways narrow and swell, making it difficult to breathe.
- Trial name
- AIM4:Next Step (NCT06572228)
- Testing
- dupilumab, ICS/LABA
- Where
- 77 sites in United States, Canada and 4 more
- Volunteers
- 120 people
- Sponsor
- Regeneron Pharmaceuticals
Allergic Asthma
A Phase IIa Study of Subcutaneous AER 001 on Antigen Challenge In Atopic Asthmatic Subjects (28 Day Study)
This is a single center, double-blind, randomised parallel group design study to investigate the effects of AER 001 on the late phase asthmatic resonse in asthmatic subjects.
- Trial name
- NCT00535028
- Testing
- AER 001
- Where
- United Kingdom
- Volunteers
- 24 people
- Sponsor
- Aerovance, Inc.
Asthma
Study to Assess Airway Inflammation Effects of FlutiForm® pMDI Low and High Dose in Adults With Mild to Moderate Asthma
This is a dose-response study to determine how various measurements of airway inflammation respond to high and low dose FlutiForm®, and compared to placebo.
- Trial name
- FLT2503 (NCT00995800)
- Testing
- Fluticasone propionate / Formoterol fumarate
- Where
- Germany
- Volunteers
- 46 people
- Sponsor
- Mundipharma Research Limited
COPD, Particulate Matter Induced Inflammation of the Lung
Efficacy and Feasibility of Ectoin® Inhalation Solution in Inflammatory Obstruction and Ageing of the Lung
To investigate the physical inflammation inhibition effects of EIL (Ectoin-Hydro-Complex) in subjects of the established SALIA-cohort and the preventive effects on lung function decline.
- Trial name
- EFECT (NCT01225965)
- Testing
- Ectoin Inhalation Solution
- Where
- Germany
- Volunteers
- 36 people
- Sponsor
- Bitop AG
Systemic Lupus Erythematosus, Sjögren's Disease
A Study of BMS-986553 in Participants With Refractory Autoimmune Diseases
The purpose of this study is to evaluate the safety and tolerability of BMS-986553, CD19 in vivo Chimeric Antigen Receptor (CAR) T cells, in participants with refractory autoimmune diseases including systemic lupus erythematosus…
- Conditions
- Systemic Lupus Erythematosus, Sjögren's Disease, Rheumatoid Arthritis, Idiopathic Inflammatory Myopathies
- Trial name
- NCT07873931
- Testing
- BMS-986553
- Where
- 23 sites in United States, Belgium and 4 more
- Volunteers
- 60 people
- Sponsor
- Bristol-Myers Squibb
Asthma
A Phase IIA FF/VI Study to Measure FeNO in Asthmatic Patients.
For asthmatic subjects, a combination of inhaled corticosteroid (FF) and long-acting beta2 receptor agonist (VI) is recommended for use (once daily) and fraction of exhaled nitric oxide (FeNO) is a non-invasive airway…
- Trial name
- NCT02712047
- Testing
- Fluticasone furoate (FF) (100 mcg), Vilanterol (VI) (25 mcg)
- Where
- New Zealand
- Volunteers
- 28 people
- Sponsor
- GlaxoSmithKline
Sepsis, Renal Failure
The Prevention of Failure to Rescue Using Early Warning Scoring
The purpose of this study is to assess if, compared with standard paper-based systems, an automated Early Warning System (EWS) resident in a spot check patient monitor, can help to identify deteriorating patients.
- Conditions
- Sepsis, Renal Failure, Pulmonary Edema, Cardio-pulmonary Arrest
- Trial name
- VitalCare (NCT01197326)
- Testing
- use of the MP5 EWS patient monitor
- Where
- Australia
- Volunteers
- 414 people, healthy volunteers welcome
- Sponsor
- Philips Healthcare
Atopic Keratoconjunctivitis
An Efficacy and Safety Study of DFL24498 in the Treatment of AKC
This is a phase 3, multicenter, randomized, double-masked, parallel-group, vehicle-controlled study to evaluate the safety and efficacy of DFL24498 compared with vehicle ophthalmic solution, in participants with AKC.
- Trial name
- NCT07395232
- Testing
- DFL24498, Vehicle, dexamethasone sodium phosphate (DSP) ophthalmic solution
- Where
- 19 sites in United States, Italy and 1 more
- Volunteers
- 153 people
- Sponsor
- Dompé Farmaceutici S.p.A
Sepsis
Can Respiratory Rate Predict the Risk of Deterioration of Septic Patients
The primary objective is to determine if the trend in Respiratory Rate measurements provided by the device under investigation can be used to predict an increase in Sequential/Sepsis-related Organ Failure Assessment (SOFA) score.
- Trial name
- NCT03752047
- Where
- Denmark
- Volunteers
- 132 people
- Sponsor
- PMD Solutions
Cystic Fibrosis
Inhaled Sodium Pyruvate for the Treatment of Cystic Fibrosis.
It is hypothesized that the inhalation of sodium pyruvate will reduce lung damage in patients with Cystic Fibrosis (CF) by its ability to reduce levels of toxic reactive oxygen and nitrogen compounds associated with the chronic…
- Trial name
- NCT00308243
- Testing
- Sodium Pyruvate in 0.9% Sodium Chloride Solution
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Emphycorp
Immunity, Vaccine Reaction
Efficacy and Tolerability of ABBC1 in Volunteers Receiving the Influenza or Covid-19 Vaccine
The immune system response needs to be forceful but also balanced for a rapid recovery from infection which avoids harmful overreactions.
- Conditions
- Immunity, Vaccine Reaction, Influenza, Covid19
- Trial name
- NCT04798677
- Testing
- ABBC1 Immunoessential
- Where
- Spain
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- AB Biotek
Covid19
LLLT Treatment of Lung Inflammation in COVID-19
To determine if a reduction of pneumonic inflammation occurs after treatment with Low-Level Laser Therapy (LLLT) applying red-light technology in the respiratory system of COVID-19 patients suffering from acute viral pneumonia.
- Trial name
- NCT04524715
- Testing
- Non-invasive red LLLT treatment to chest of patient.
- Where
- United States
- Sponsor
- Ward Photonics LLC
Chronic Cough
A Clinical Trial to Evaluate the Safety and Efficacy in Subjects With Chronic Cough
A Randomized, Double-Blind, Placebo-Controlled, Two-Period Crossover, Phase 2 Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of ADX-629 Administered Orally to Subjects with Chronic Cough
- Trial name
- NCT05392192
- Testing
- ADX-629
- Where
- 14 sites in United States
- Volunteers
- 51 people
- Sponsor
- Aldeyra Therapeutics, Inc.
Sepsis, Septicemia
A Rapid Diagnostic of Risk in Hospitalized Patients Using Machine Learning
In this study, the investigators will deploy a software-based clinical decision support tool (eCARTv5) into the electronic health record (EHR) workflow of multiple hospital wards.
- Conditions
- Sepsis, Septicemia, Respiratory Failure, Hemodynamic Instability
- Trial name
- NCT05893420
- Testing
- eCARTv5 clinical deterioration monitoring, Standard of care control
- Where
- 3 sites in United States
- Volunteers
- 30,000 people
- Sponsor
- AgileMD, Inc.
SARS-CoV2 Infection
Efficacy and Safety of EXOSOME-MSC Therapy to Reduce Hyper-inflammation In Moderate COVID-19 Patients
In COVID-19 infection caused by the Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), there is a dysregulation of the immune system response that causes cytokine storm syndrome.
- Trial name
- EXOMSC-COV19 (NCT05216562)
- Testing
- Exosome-MSC Intravenous injection, COVID-19 Standard Treatment
- Where
- 3 sites in Indonesia
- Volunteers
- 60 people
- Sponsor
- Dermama Bioteknologi Laboratorium
Respiratory Distress Syndrome, Adult
Evaluation of Safety & Efficacy of BIO-11006 Inhalation Solution in Patients With ARDS
This Phase IIa pilot study is a placebo controlled, multicenter study to evaluate safety and efficacy of aerosolized BIO-11006 Inhalation Solution in ARDS patients.
- Trial name
- NCT03202394
- Testing
- BIO-11006
- Where
- 5 sites in United States
- Volunteers
- 38 people
- Sponsor
- BioMarck Pharmaceuticals, Ltd.
Asthma
SMILDA - Symbicort®Turbuhaler® Allergan Challenge Study in Allergic Patients With Mild Asthma
To compare the effects of formoterol alone (Oxis® TurbuhalerÒ) and the fixed combination of formoterol and budesonide (Symbicort® TurbuhalerÒ) on airway responsiveness as a marker of inflammation, induced by repeated low-dose…
- Trial name
- NCT00288379
- Testing
- formoterol, budesonide/formoterol
- Where
- Sweden
- Volunteers
- 16 people
- Sponsor
- AstraZeneca